QGEN Jul 2024 40.000 call
| Previous Close | 4.1000 |
| Open | 3.5000 |
| Bid | 6.1000 |
| Ask | 6.3000 |
| Strike | 40.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 3.5000 - 4.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 10 |
ZacksQIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.
GlobeNewswireQIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight InterpretVenlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
ZacksQIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.
